1-7 of 7
Jingsong Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)

Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Channing J. Paller, Joel Picus, Zachery R. Reichert, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Latifa A. Bazzi, Stephanie Daignault-Newton, Young E. Whang, Robert Dreicer, Ryan D. Stephenson, Matthew B. Rettig, Daniel Shevrin, Travis Gerke, Arul M. Chinnaiyan, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4318–4328.
https://doi.org/10.1158/1078-0432.CCR-24-1402
Published: 01 October 2024
View article titled, Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Open the PDF for Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) in another window
Includes: Supplementary data
Journal Articles

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng, Emmanuel S. Antonarakis, Rana R. McKay, Russell K. Pachynski, Jingsong Zhang, Zachery R. Reichert, Phillip L. Palmbos, Megan E.V. Caram, Ulka N. Vaishampayan, Elisabeth I. Heath, Alexander C. Hopkins, Marcin P. Cieslik, Yi-Mi Wu, Dan R. Robinson, Veerabhadran Baladandayuthapani, Arul M. Chinnaiyan, Ajjai S. Alva
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3200–3210.
https://doi.org/10.1158/1078-0432.CCR-24-0400
Published: 01 August 2024
View article titled, Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious <em>CDK12</em> Alterations in the Phase 2 IMPACT Trial
Open the PDF for Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious <em>CDK12</em> Alterations in the Phase 2 IMPACT Trial in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder

Roger Li, Wade J. Sexton, Jasreman Dhillon, Anders Berglund, Shreyas Naidu, Gustavo Borjas, Kyle Rose, Youngchul Kim, Xuefeng Wang, Jose R. Conejo-Garcia, Rohit K. Jain, Michael A. Poch, Philippe E. Spiess, Julio Pow-Sang, Scott M. Gilbert, Jingsong Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3875–3881.
https://doi.org/10.1158/1078-0432.CCR-23-0354
Published: 02 October 2023
View article titled, A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <em>In Situ</em> of the Bladder
Open the PDF for A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <em>In Situ</em> of the Bladder in another window
Includes: Supplementary data
Journal Articles

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study

Andrea Loehr, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H. Bryce, Ray McDermott, Brieuc Sautois, Nicholas J. Vogelzang, Richard M. Bambury, Eric Voog, Jingsong Zhang, Josep M. Piulats, Arif Hussain, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S. Higano, Laurence E. Krieger, Cora N. Sternberg, Simon P. Watkins, Darrin Despain, Andrew D. Simmons, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, Wassim Abida
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6677–6686.
https://doi.org/10.1158/1078-0432.CCR-21-2199
Published: 15 December 2021
View article titled, Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Open the PDF for Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study in another window
Includes: Supplementary data
Journal Articles

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

Wassim Abida, David Campbell, Akash Patnaik, Jeremy D. Shapiro, Brieuc Sautois, Nicholas J. Vogelzang, Eric G. Voog, Alan H. Bryce, Ray McDermott, Francesco Ricci, Julie Rowe, Jingsong Zhang, Josep Maria Piulats, Karim Fizazi, Axel S. Merseburger, Celestia S. Higano, Laurence E. Krieger, Charles J. Ryan, Felix Y. Feng, Andrew D. Simmons, Andrea Loehr, Darrin Despain, Melanie Dowson, Foad Green, Simon P. Watkins, Tony Golsorkhi, Simon Chowdhury
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2487–2496.
https://doi.org/10.1158/1078-0432.CCR-20-0394
Published: 01 June 2020
View article titled, Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Open the PDF for Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study in another window
Includes: Supplementary data
Journal Articles

Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy

Jeffrey B. West, Mina N. Dinh, Joel S. Brown, Jingsong Zhang, Alexander R. Anderson, Robert A. Gatenby
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4413–4421.
https://doi.org/10.1158/1078-0432.CCR-19-0006
Published: 15 July 2019
View article titled, Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy
Open the PDF for Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer

Shilpa Gupta, Luke T. Nordquist, Mark T. Fleming, William R. Berry, Jingsong Zhang, Sharon L. Ervin, Joel R. Eisner, Edwina S. Baskin-Bey, Neal D. Shore
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (21): 5225–5232.
https://doi.org/10.1158/1078-0432.CCR-18-0564
Published: 01 November 2018
View article titled, Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Open the PDF for Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data